Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Super Group (SGHC) Limited Ordinary Shares (SGHC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Super Group (SGHC) Limited Ordinary Shares — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Super Group (SGHC) Limited Ordinary Shares trades at $11.1 (market cap $5.69B). The key difference: Super Group (SGHC) Limited Ordinary Shares is far larger — about 5.8× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Super Group (SGHC) Limited Ordinary Shares pays a 1.79% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Super Group (SGHC) Limited Ordinary Shares for 6 Days on average.
| MRVI | SGHC | |
|---|---|---|
Market Cap | $972.90M | $5.69B |
Volume | 4,325,710 | 2,162,759 |
Sector | Health | Consumer Cyclical |
52-Week High | $9.00 | $15.59 |
52-Week Low | $2.83 | $8.52 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $1.08B | $5.23B |
Dividend Yield | — | 1.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
SGHC trades at $11.19, down 0.27% with a bearish technical signal despite strong fundamentals. The company shows robust profitability with 53.31% gross margins and 48.9% ROE, while revenue grew to $2.23B in 2025. Recent earnings missed expectations but analyst consensus remains unanimously bullish with 8 buy ratings. Technical indicators show selling pressure with moving averages signaling bearish momentum.
SGHC presents a compelling value opportunity with attractive valuation multiples (P/E 15.55, EV/EBITDA 8.43) and strong cash flow generation. However, recent earnings misses and bearish technical signals create near-term headwinds. The stock's outlook depends on Q3 earnings delivery and sustained sports betting momentum amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Super Group (SGHC) Limited Ordinary Shares
Super Group (SGHC) Limited is a holding company for online sports betting and gaming businesses, operating the Betway sports betting brand and the Spin multi-brand online casino portfolio across markets in Europe, the Americas, and Africa.
Read more on SGHC →
